吉利德科学公司周一表示，其实验性的每日一次口服药片在中期试验中减少了比安慰剂更多患者的慢性肠道疾病症状。
Gilead Sciences said on Monday its experimental once-daily pill reduced symptoms of a chronic bowel illness in more patients than placebo in a mid-stage trial.
该药物名为埃维司他格，正在接受中度至重度溃疡性结肠炎成年患者的测试，这是一种导致消化道炎症和溃疡的慢性疾病。该药片旨在阻断α4β7整合素通路，这一靶点已在炎症性肠病中得到验证。经过12周，服用200毫克剂量药物的患者中有66%出现病情症状改善，而安慰剂组为37%，达到了试验的主要目标。此外，接受治疗的患者中有31%达到临床缓解，而安慰剂组仅为8%。
BMO资本市场分析师表示，他们认为这些数据是“吉利德炎症策略的渐进式积极进展，确立了埃维司他格作为可靠的口服α4β7选择”。
The drug, emvistegrast, was being tested in adults with moderate to severe ulcerative colitis, a chronic condition that causes inflammation and ulcers in the digestive tract The pill is designed to block the α4β7 integrin pathway, a target already validated in inflammatory bowel disease After 12 weeks, 66% of patients taking a 200 mg dose of the drug saw their disease symptoms improve, compared to 37% on placebo, meeting the trial's main goal Also, 31% of patients receiving the treatment achieved clinical remission, compared to 8% of those in the placebo group BMO Capital Markets analysts said they view the data as "an incremental positive for Gilead's inflammatory strategy that establishes emvistegrast as a credible oral α4β7 option"
该药物总体耐受性良好，治疗组和安慰剂组的总体不良反应率相当，且未发现与研究药物相关的严重不良反应。吉利德表示，计划于2027年启动该药片的晚期单药疗法研究。
The drug was generally well tolerated, with overall side-effect rates comparable between the treatment and placebo groups, and no serious side effects were linked to the study medication Gilead said it plans to initiate a late-stage monotherapy study of the pill in 2027